Board approves Q1 FY26-27 results, new auditor and AGM on Sep 11

Revenue DeclinePat Growth 25pctRelated Party TransactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-5.7%1-day move

₹39.25

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-5.7-3.3-4.4-3.2-3.2-3.2-3.1-5.8——

Up moveDown movePending

AI summary

Sandu Pharmaceuticals Board approved Q1 FY26-27 standalone results with unmodified auditor opinion. Revenue dipped to Rs. 1638.88 lakhs from Rs. 1669.90 lakhs YoY, but PAT rose to Rs. 29.78 lakhs from Rs. 23.3 lakhs; EPS rose to Rs. 0.37 from Rs. 0.23. The 41st AGM is set for September 11, 2026 via video conferencing, with record date September 4, 2026 for dividend. Board appointed M/s. Dave and Dave as new statutory auditors for a 5-year term. Recommended member approval for material related party deals with Sandu Brothers Pvt Ltd.

Likely market impact

Revenue decline offset by strong PAT growth suggests margin improvement. New auditor and pending RPT approval may raise governance questions.